selected scholarly activity
-
conferences
- eP160: Bilateral oophorectomy and the risk of breast cancer in women with a pathogenic variant in BRCA1: A reappraisal. Genetics in Medicine. S98-S98. 2022
- eP299: Genetics adviser: The development and usability testing of a new patient-centered digital health application to support clinical genomic testing. Genetics in Medicine. S190-S190. 2022
- eP392: A comprehensive genomic test reporting structure for communicating cancer and incidental findings. Genetics in Medicine. S247-S247. 2022
- Weight Gain and the Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology, Biomarkers and Prevention. 2038-2043. 2021
- Contraceptive use and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers: A prospective cohort study.. Cancer Research. 2021
- Assessing burnout among oncologists in Ontario, Canada.. Journal of Clinical Oncology. 2020
- A validated algorithm for the identification of a new outcome measure from administrative data: The Breast Cancer Recurrence Project. Annals of Surgical Oncology. 385-386. 2018
- Practitioner opinion on contralateral prophylactic mastectomy: How do we steer a patient-driven discussion?. Annals of Surgical Oncology. 324-325. 2018
- Abstract P3-02-06: Magnetic resonance imaging (MRI) surveillance for patients with dense breasts and a previous breast cancer (BC) and/or high risk lesion. Cancer Research. 2017
- Prospective evaluation of the impact of the 21-gene recurrence score® assay on adjuvant treatment decisions for women with node-positive breast cancer in Ontario, Canada. Annals of Oncology. vi54-vi54. 2016
- Impact of the 21-gene Recurrence Score assay on the adjuvant treatment of breast cancer patients with 1-3 positive lymph nodes in an academic centre in Ontario.. Journal of Clinical Oncology. e12026-e12026. 2016
- Using a disease pathway management approach to improve the quality of breast cancer care in Ontario.. Journal of Clinical Oncology. 109-109. 2016
- 2508 Three-arm phase II randomized trial of docetaxel monotherapy or combined with ramucirumab or icrucumab in second-line locally advanced or metastatic urothelial carcinoma. European Journal of Cancer. S476-S476. 2015
- Population-based evaluation of 21-gene assay in treatment decision making for early breast cancer in Ontario.. Journal of Clinical Oncology. 583-583. 2014
- Genomic testing in cancer (GTC): Patient knowledge, attitudes and expectations. European Journal of Cancer. S195-S196. 2013
- The first 10 years experience with genetic testing (GT) for BRCA1/2 mutations in a publicly funded program at a tertiary care teaching hospital in Ontario, Canada. Journal of Clinical Oncology. 2013
- Abstract P2-12-03: A pilot study evaluating the benefits and feasibility of an exercise program for breast cancer patients receiving adjuvant chemotherapy.. Cancer Research. 2012
- Results of a phase II study of single-agent nab-paclitaxel in platinum-refractory second-line metastatic urothelial carcinoma (UC). Journal of Clinical Oncology. 2011
- A MULTI-INSTITUTIONAL PHASE II STUDY OF SINGLE AGENT ABI-007 IN PLATINUM REFRACTORY UROTHELIAL CARCINOMA. Annals of Oncology. 280-280. 2010
- A phase II study of single-agent nab-paclitaxel as second-line therapy in patients with metastatic urothelial carcinoma.. Journal of Clinical Oncology. TPS231-TPS231. 2010
- Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163. Journal of Clinical Oncology. 4536-4541. 2009
- A phase II study of single agent abraxane as second-line therapy in patients with advanced urothelial carcinoma. Journal of Clinical Oncology. 2009
- A systematic review of the role of adjuvant ovarian ablation in the treatment of women with early stage breast cancer.. Breast Cancer Research and Treatment. S121-S121. 2007
- Benefit from exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): intent-to-treat analysis of NSABP B-33.. Breast Cancer Research and Treatment. S22-S22. 2006
- Clinics and epidemiology of hereditary breast cancer. Toxicology Letters. S2-S4. 2005
- Frequency of axillary node dissection and chemotherapy in breast cancer patients over 60 years of age compared with those younger than 60 years of age.. Journal of Clinical Oncology. 769S-769S. 2004
- Adherence to cancer risk reduction strategies in unaffected women who attend a breast and ovarian cancer risk reduction clinic.. Breast Cancer Research and Treatment. S153-S154. 2004
- Ten-year outcome of breast-conserving surgery (BCS) and radiotherapy (RT) in women with breast cancer (BC) and germline BRCA 1/2 mutations: results from an international collaboration. Breast Cancer Research and Treatment. S7-S7. 2003
- Urgent genetic assessment (GA) in the management of newly diagnosed familial breast cancer (br ca) patients: a feasibility study. Breast Cancer Research and Treatment. S76-S77. 2003
- Fellowships in Research and Science Teaching (FIRST), a model for a holistic post-doctoral education. Molecular Biology of the Cell. 416A-416A. 2002
- Decision making factors associated with whether to receive BRCA1/2 genetic test results. European Journal of Human Genetics. 325-325. 2002
-
journal articles
- "Should I let them know I have this?": Multifaceted genetic discrimination and limited awareness of legal protections amongst individuals with hereditary cancer syndromes.. Public health genomics. 27:1-21. 2024
- Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in BRCA1 and BRCA2.. Journal of Clinical Oncology. JCO2400176. 2024
- Incidence of endometrial cancer in BRCA mutation carriers.. Gynecologic Oncology. 189:148-155. 2024
- Rates of genetic consultation in high-grade serous ovarian cancer patients in the era of PARP inhibitor therapy: A population-based study.. International Journal of Gynecology and Obstetrics. 166:282-289. 2024
- Mainstream Model of Genetic Testing for Prostate Cancer at a Large Tertiary Cancer Centre. Clinical Genitourinary Cancer. 22:102052-102052. 2024
- Implementing Multifactorial Risk Assessment with Polygenic Risk Scores for Personalized Breast Cancer Screening in the Population Setting: Challenges and Opportunities. Cancers. 16:2116-2116. 2024
- The risk of skin cancer in women who carry BRCA1 or BRCA2 mutations. Hereditary Cancer in Clinical Practice. 22:7. 2024
- Bilateral Oophorectomy and All-Cause Mortality in Women With BRCA1 and BRCA2 Sequence Variations. JAMA Oncology. 10:484-484. 2024
- Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY.. Breast Cancer Research and Treatment. 204:237-248. 2024
- MRI Surveillance and Breast Cancer Mortality in Women With BRCA1 and BRCA2 Sequence Variations. JAMA Oncology. 10:493-493. 2024
- Risk-reducing mastectomy and breast cancer mortality in women with a BRCA1 or BRCA2 pathogenic variant: an international analysis. British Journal of Cancer. 130:269-274. 2024
- Breast Magnetic Resonance Imaging for Preoperative Evaluation of Breast Cancer: A Systematic Review and Meta-Analysis. Canadian Association of Radiologists Journal. 75:118-135. 2024
- Genetics Adviser: The development and usability testing of a new patient digital health application to support clinical genomic testing. Genetics in Medicine Open. 2:101814. 2024
- “I don’t need any more unknowns hanging over my head”: Views of patients with cancer on variants of uncertain significance and low/moderate risk results from genomic sequencing. Genetics in Medicine. 25:100960-100960. 2023
- Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a BRCA1 or BRCA2 Mutation. Cancer Research Communications. 3:2420-2429. 2023
- Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation. Breast Cancer Research and Treatment. 201:257-264. 2023
- Impact of 18F-Labeled Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Versus Conventional Staging in Patients With Locally Advanced Breast Cancer. Journal of Clinical Oncology. 41:3909-3916. 2023
- A model for the return and referral of all clinically significant secondary findings of genomic sequencing. Journal of Medical Genetics. 60:733-739. 2023
- Preoperative Breast Magnetic Resonance Imaging: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline. Current Oncology. 30:6255-6270. 2023
- The risks of cancer in older women with BRCA pathogenic variants: How far have we come?. Cancer. 129:901-907. 2023
- A comprehensive genomic reporting structure for communicating all clinically significant primary and secondary findings. Human Genetics. 141:1875-1885. 2022
- Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Annals of Oncology. 33:1250-1268. 2022
- Identifying Breast Cancer Recurrence in Administrative Data: Algorithm Development and Validation. Current Oncology. 29:5338-5367. 2022
- Bilateral Oophorectomy and the Risk of Breast Cancer in BRCA1 Mutation Carriers: A Reappraisal. Cancer Epidemiology, Biomarkers and Prevention. 31:1351-1358. 2022
- A systematic review of axillary nodal irradiation for the management of the axilla in patients with early-stage breast cancer. Surgical Oncology. 42:101754-101754. 2022
- VP1-2022: Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer. Annals of Oncology. 33:566-568. 2022
- Widening the lens of actionability: A qualitative study of primary care providers’ views and experiences of managing secondary genomic findings. European Journal of Human Genetics. 30:595-603. 2022
- Clinical Utility of Multigene Profiling Assays in Early-Stage Invasive Breast Cancer: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline. Current Oncology. 29:2599-2615. 2022
- Genetics Adviser: a protocol for a mixed-methods randomised controlled trial evaluating a digital platform for genetics service delivery. BMJ Open. 12:e060899-e060899. 2022
- Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. Gynecologic Oncology. 164:514-521. 2022
-
The risks of breast and ovarian cancer associated with the Ashkenazi Jewish founder allele
BRCA2 6174delT . Clinical Genetics. 101:317-323. 2022 - Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update. Journal of Clinical Oncology. 40:787-800. 2022
- Challenges and practical solutions for managing secondary genomic findings in primary care. European Journal of Medical Genetics. 65:104384-104384. 2022
- Evaluation of a decision aid for incidental genomic results, the Genomics ADvISER: protocol for a mixed methods randomised controlled trial. BMJ Open. 8:e021876-e021876. 2022
- Prevalence and Workplace Drivers of Burnout in Cancer Care Physicians in Ontario, Canada. JCO Oncology Practice. 18:e60-e71. 2022
- Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline. Journal of Clinical Oncology. 39:3056-3082. 2021
- Should Age-Dependent Absolute Risk Thresholds Be Used for Risk Stratification in Risk-Stratified Breast Cancer Screening?. Journal of Personalized Medicine. 11:916-916. 2021
- Abstract 878: Contraceptive use and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers: A prospective cohort study. Cancer Research. 81:878-878. 2021
- Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration and Implementation (PERSPECTIVE I&I). Journal of Personalized Medicine. 11:511-511. 2021
- Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment. 187:515-523. 2021
- Weight gain and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Molecular Genetics and Metabolism. 132:S357-S358. 2021
- Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation. Gynecologic Oncology. 159:820-826. 2020
- Impact of rarity on Canadian oncology health technology assessment and funding. International Journal of Technology Assessment in Health Care. 36:404-409. 2020
- Baseline Staging Imaging for Distant Metastasis in Women with Stages I, II, and III Breast Cancer. Current Oncology. 27:123-145. 2020
- Predictors of mammographic density among women with a strong family history of breast cancer. BMC Cancer. 19:631. 2019
- Practitioner Opinion on Contralateral Prophylactic Mastectomy: How Do We Steer a Patient-Driven Discussion?. Annals of Surgical Oncology. 26:3489-3494. 2019
- International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. British Journal of Cancer. 121:15-21. 2019
- A priori prediction of breast tumour response to chemotherapy using quantitative ultrasound imaging and artificial neural networks. Oncotarget. 10:3910-3923. 2019
- Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment. 175:443-449. 2019
- Impact of a Novel Prioritization Framework on Clinician-Led Oncology Drug Submissions. Current Oncology. 26:155-161. 2019
- Response to: The Survival Time of 8376 Male Breast Cancer Patients. Clinical Oncology. 30:818-819. 2018
- Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers. JAMA Oncology. 4:1059-1059. 2018
- Prospective Evaluation of the Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node-Positive Breast Cancer in Ontario, Canada. Oncologist. 23:768-775. 2018
- Serum osteoprotegerin levels and mammographic density among high-risk women. Cancer Causes and Control. 29:507-517. 2018
- The association between smoking and cancer incidence in BRCA1 and BRCA2 mutation carriers. International Journal of Cancer. 142:2263-2272. 2018
- Treatment Outcomes in Male Breast Cancer: A Retrospective Analysis of 161 Patients. Clinical Oncology. 30:354-365. 2018
- Data sharing as a national quality improvement program: reporting on BRCA1 and BRCA2 variant-interpretation comparisons through the Canadian Open Genetics Repository (COGR). Genetics in Medicine. 20:294-302. 2018
- Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology–Cancer Care Ontario Focused Guideline Update. Journal of Clinical Oncology. 35:3978-3986. 2017
- Breast screening for survivors of breast cancer: A systematic review. Preventive Medicine. 103:70-75. 2017
- Clinical Utility of Multigene Profiling Assays in Early-Stage Breast Cancer. Current Oncology. 24:403-422. 2017
- Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial. Journal of Clinical Oncology. 34:1500-1509. 2016
- The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study. British Journal of Cancer. 114:1160-1164. 2016
- Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario. Journal of Clinical Oncology. 34:1065-1071. 2016
- The effect of melatonin on sleep and quality of life in patients with advanced breast cancer. Supportive Care in Cancer. 24:1097-1105. 2016
- Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. Fertility and Sterility. 105:781-785. 2016
- Canadian Open Genetics Repository (COGR): a unified clinical genomics database as a community resource for standardising and sharing genetic interpretations. Journal of Medical Genetics. 52:438-445. 2015
- Adjuvant Chemotherapy for Early Female Breast Cancer: A Systematic Review of the Evidence for the 2014 Cancer Care Ontario Systemic Therapy Guideline. Current Oncology. 22:82-94. 2015
- Adjuvant Endocrine Therapy for Early Breast Cancer: A Systematic Review of the Evidence for the 2014 Cancer Care Ontario Systemic Therapy Guideline. Current Oncology. 22:95-113. 2015
- Locoregional Therapy of Locally Advanced Breast Cancer: A Clinical Practice Guideline. Current Oncology. 22:54-66. 2015
- Optimal Systemic Therapy for Early Breast Cancer in Women: A Clinical Practice Guideline. Current Oncology. 22:67-81. 2015
- Systemic Targeted Therapy for her2-Positive Early Female Breast Cancer: A Systematic Review of the Evidence for the 2014 Cancer Care Ontario Systemic Therapy Guideline. Current Oncology. 22:114-122. 2015
- Prospective study of high-risk, BRCA1/2-mutation negative women: the ‘negative study’. BMC Cancer. 14:221. 2014
- Genomic testing in cancer: Patient knowledge, attitudes, and expectations. Cancer. 120:3066-3073. 2014
- Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment. 146:421-427. 2014
- Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study. The Lancet Oncology. 14:769-776. 2013
- Management of carcinoma of the penis: Consensus statement from the Canadian Association of Genitourinary Medical Oncologists (CAGMO). Journal of the Canadian Urological Association. 7:797-797. 2013
- Management of small cell carcinoma of the bladder: Consensus guidelines from the Canadian Association of Genitourinary Medical Oncologists (CAGMO). Journal of the Canadian Urological Association. 7:44-44. 2013
- Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research. 14:R42. 2012
- A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium. Investigational New Drugs. 29:1045-1049. 2011
- The symptom appraisal of breast cancer in the context of an intimate relationship. Journal of Health Psychology. 16:653-666. 2011
- Results of a phase II study of single-agent nab-paclitaxel in platinum-refractory second-line metastatic urothelial carcinoma (UC).. Journal of Clinical Oncology. 29:241-241. 2011
- Does family history predict the age at onset of new breast cancers in BRCA1 and BRCA2 mutation‐positive families?. Clinical Genetics. 77:273-279. 2010
- A phase II study of single agent abraxane as second-line therapy in patients with advanced urothelial carcinoma. Journal of Clinical Oncology. 27:e16058-e16058. 2009
- Preferential Killing of Breast Tumor Initiating Cells by N,N-Diethyl-2-[4-(Phenylmethyl)Phenoxy]Ethanamine/Tesmilifene. Clinical Cancer Research. 15:119-130. 2009
- Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case–control study. Cancer Causes and Control. 19:1111-1119. 2008
- Hormone Therapy and the Risk of Breast Cancer in BRCA1 Mutation Carriers. Journal of the National Cancer Institute. 100:1361-1367. 2008
- Rapid progression of prostate cancer in men with a BRCA2 mutation. British Journal of Cancer. 99:371-374. 2008
- Systematic Review: Using Magnetic Resonance Imaging to Screen Women at High Risk for Breast Cancer. ACP journal club. 148:671-671. 2008
- International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. International Journal of Cancer. 122:2017-2022. 2008
- Benefit From Exemestane As Extended Adjuvant Therapy After 5 Years of Adjuvant Tamoxifen: Intention-to-Treat Analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial. Journal of Clinical Oncology. 26:1965-1971. 2008
- Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: A systematic review. Cancer Treatment Reviews. 34:157-174. 2008
- Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment. 105:221-228. 2007
- Clinical Management Recommendations for Surveillance and Risk-Reduction Strategies for Hereditary Breast and Ovarian Cancer Among Individuals Carrying a Deleterious BRCA1 or BRCA2 Mutation. Journal of Obstetrics and Gynaecology Canada. 29:45-60. 2007
- Ten-Year Multi-Institutional Results of Breast-Conserving Surgery and Radiotherapy in BRCA1/2-Associated Stage I/II Breast Cancer. Journal of Clinical Oncology. 24:2437-2443. 2006
- Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update. International Journal of Cancer. 118:2281-2284. 2006
- Spontaneous and therapeutic abortions and the risk of breast cancer among BRCAmutation carriers. Breast Cancer Research. 8:R15. 2006
- Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Causes and Control. 16:667-674. 2005
- Contralateral Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. Journal of Clinical Oncology. 22:2328-2335. 2004
- Role of aromatase inhibitors in the treatment of postmenopausal women with metastatic breast cancer. Current Oncology. 11:41-52. 2004
- Application of Breast Cancer Risk Prediction Models in Clinical Practice. Journal of Clinical Oncology. 21:593-601. 2003
- Review: breast cancer is associated with a family history of the disease in first degree relatives. Evidence-Based Nursing. 5:89-89. 2002
- Prophylactic Mastectomy for Women withBRCA1andBRCA2Mutations — Facts and Controversy. New England Journal of Medicine. 345:207-208. 2001
- Anthracycline Adjuvant Chemotherapy: How Much Is Enough?. Journal of Clinical Oncology. 19:599-601. 2001
- Prophylactic surgery: Oophorectomy or adnexectomy? Reply. Journal of Clinical Oncology. 18:3455-3455. 2000
-
other
- Data from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation 2023
- Data from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation 2023
- FIGURE 1 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation 2023
- FIGURE 1 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation 2023
- Supplementary Table 1 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation 2023
- Supplementary Table 1 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation 2023
- Supplementary Table 2 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation 2023
- Supplementary Table 2 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation 2023
- Supplementary Table 3 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation 2023
- Supplementary Table 3 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation 2023
- Supplementary Table 4 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation 2023
- Supplementary Table 4 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation 2023
- Supplementary Table 5 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation 2023
- Supplementary Table 5 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation 2023
- Supplementary Table 6 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation 2023
- Supplementary Table 6 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation 2023
- Supplementary Table 7 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation 2023
- Supplementary Table 7 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation 2023
- TABLE 1 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation 2023
- TABLE 1 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation 2023
- TABLE 2 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation 2023
- TABLE 2 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation 2023
- TABLE 3 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation 2023
- TABLE 3 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation 2023
- TABLE 4 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation 2023
- TABLE 4 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation 2023